

- Stroke Association: AHA Scientific Statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. *Stroke* 32: 1458–1471, 2001
- 14) Park RC, Duff WP: Role of cesarean hysterectomy in modern obstetric practice. *Clin Obstet Gynecol* 23: 601–620, 1980
 - 15) Robinson JL, Hall CS, Sedzimir CB: Arteriovenous malformations, aneurysms, and pregnancy. *J Neurosurg* 41: 63–70, 1974
 - 16) Sadasivan B, Malik GM, Lee C, Ausman JI: Vascular malformations and pregnancy. *Surg Neurol* 33: 305–313, 1990
 - 17) Salvati A, Ferrari C, Chiumarulo L, Medicamento N, Dicuonzo F, De Blasi R: Endovascular treatment of brain arteriovenous malformations ruptured during pregnancy—a report of two cases. *J Neurol Sci* 308: 158–161, 2011
 - 18) Skidmore FM, Williams LS, Fradkin KD, Alonso RJ, Biller J: Presentation, etiology, and outcome of stroke in pregnancy and puerperium. *J Stroke Cerebrovasc Dis* 10: 1–10, 2001
 - 19) Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. *J Neurosurg* 65: 476–483, 1986
 - 20) Takahashi JC, Ikeda T, Iihara K, Miyamoto S: Pregnancy and delivery in moyamoya disease: results of a nationwide survey in Japan. *Neurol Med Chir (Tokyo)* 52: 304–310, 2012
 - 21) Taylor CL, Dutton K, Rappard G, Pride GL, Replogle R, Purdy PD, White J, Giller C, Kopitnik TA Jr, Samson DS: Complications of preoperative embolization of cerebral arteriovenous malformations. *J Neurosurg* 100: 810–812, 2004
 - 22) Trivedi RA, Kirkpatrick PJ: Arteriovenous malformations of the cerebral circulation that rupture in pregnancy. *J Obstet Gynaecol* 23: 484–489, 2003
 - 23) Webb JA, Thomsen HS, Morcos SK: The use of iodinated and gadolinium contrast media during pregnancy and lactation. *Eur Radiol* 15: 1234–1240, 2005
 - 24) Witiw CD, Abou-Hamden A, Kulkarni AV, Silvaggio JA, Schneider C, Wallace MC: Cerebral cavernous malformations and pregnancy: hemorrhage risk and influence on obstetrical management. *Neurosurgery* 71: 626–631, 2012

Address reprint requests to: Koji Iihara, MD, PhD, Department of Neurosurgery, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan.
e-mail: kiihara@hsp.ncvc.go.jp

This article is published online with Open Access by IOS Press and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
 doi:10.3233/978-1-61499-289-9-1041

Panel Data Analysis of Cardiotocograph (CTG) Data

Hiroyuki Horio^a, Hitomi Kikuchi^b, Tomoaki Ikeda^c

^a Graduate School of Applied Informatics, University of Hyogo, Kobe, Japan

^b Department of Medical Engineering, Aino University, Osaka, Japan

^c Department of Obstetrics and Gynecology, Mie University Faculty of Medicine, Mie, Japan

Abstract and Objective

Panel data analysis is a statistical method, widely used in econometrics, which deals with two-dimensional panel data collected over time and over individuals. Cardiotocograph (CTG) which monitors fetal heart rate (FHR) using Doppler ultrasound and uterine contraction by strain gage is commonly used in intrapartum treatment of pregnant women. Although the relationship between FHR waveform pattern and the outcome such as umbilical blood gas data at delivery has long been analyzed, there exists no accumulated FHR patterns from large number of cases. As time-series economic fluctuations in econometrics such as consumption trend has been studied using panel data which consists of time-series and cross-sectional data, we tried to apply this method to CTG data. The panel data composed of a symbolized segment of FHR pattern can be easily handled, and a perinatologist can get the whole FHR pattern view from the microscopic level of time-series FHR data.

Keywords: Cardiotocogram, Fetal heart rate, Panel data analysis, FHR pattern

Introduction

Intrapartum CTG monitoring is used to prevent non-reassuring fetal status in most perinatal medical facilities and the intrapartum management guidelines based on FHR classification were proposed in major countries. In literatures, there were many individual relationship studies between characteristics of FHR waveform pattern and outcome such as umbilical arterial blood gas data at delivery. Although these previous methods were not enough flexible to deal with the accumulated large number of time-series FHR waveforms, it will be easy to handle as panel data which are filtered from the FHR waveforms to symbolized data.

Table 1 - 134 patterns for FHR classification

Moderate Variability (Amplitude 6-25 bpm)											
Deceleration			Variable			Late			Prolonged		
Baseline FHR	None	Early	Mild	Moderate	Severe	Mild	Moderate	Severe	Mild	Moderate	Severe
over 160 bpm	a1	a1	a1	a1	a1	f1	f1	f1	h1	h1	h1
110-160 bpm	a2	b2	c2	d2	e2	f2	g2	h2	i2	j2	k2
80-110 bpm	a3	b3	c3	d3	e3	f3	g3	h3	i3	j3	k3
70-80 bpm	a4	b4			e4		g4	h4			k4
below 70 bpm	a5	b5			e5		g5	h5			k5

Minimal Variability (Amplitude 3-5bpm)											
Deceleration			Variable			Late			Prolonged		
Baseline FHR	None	Early	Mild	Moderate	Severe	Mild	Moderate	Severe	Mild	Moderate	Severe
over 160 bpm	a10	b10	c10	d10	e10	f10	g10	h10	i10	j10	k10
110-160 bpm	a20	b20	c20	d20	e20	f20	g20	h20	i20	j20	k20
80-110 bpm	a30	b30	c30	d30	e30	f30	g30	h30	i30	j30	k30
70-80 bpm	a40	b40			e40		g40	h40			k40
below 70 bpm	a50	b50			e50		g50	h50			k50

Absent Variability (Amplitude <2bpm)											
Deceleration			Variable			Late			Prolonged		
Baseline FHR	None	Early	Mild	Moderate	Severe	Mild	Moderate	Severe	Mild	Moderate	Severe
over 160 bpm	a100	b100	c100	d100	e100	f100	g100	h100	i100	j100	k100
110-160 bpm	a200	b200	c200	d200	e200	f200	g200	h200	i200	j200	k200
80-110 bpm	a300	b300	c300	d300	e300	f300	g300	h300	i300	j300	k300
70-80 bpm	a400	b400			e400		g400	h400			k400
below 70 bpm	a500	b500			e500		g500	h500			k500

Marked Variability (Amplitude >26bpm)	
M	Sinusoidal FHR Pattern S

Methods

In 1909 consecutive low risk pregnancies, each 10 min-segment of the last 60 min. of vaginal delivery was retrospectively labeled into 134 patterns (Table 1) by expert perinatologist. These were used to two dimensional panel data of 10 min. patterns and individuals with the umbilical arterial blood gas data, pH, base excess (BE), PaCO₂ and PaO₂ at birth to analyze the relationship between the FHR pattern sequence and the outcome.

Results

Using the panel data, it is clear to handle each time-series FHR data as the representative segments from beginning to end of FHR monitoring for further analysis. A result was shown in Figure 1. In this analysis, each number of occurrences of deceleration in 1552 cases which had moderate variability and 110-160 bpm baseline was plotted with the pH at birth. Although all of these cases had normal FHR baseline and variability, the number of the deceleration occurrence had a significant difference with the pH at birth. Although the panel data of this study was only one hour data, it compressed the amount of time series FHR to character based length, and a perinatologist can overview the whole FHR data under the standard interpretation.





Figure 1. Relationship between umbilical arterial blood gas pH at delivery and the number of deceleration before delivery from FHR panel data.



A novel reproducible model of neonatal stroke in mice: Comparison with a hypoxia–ischemia model



Masahiro Tsuji^{a,*}, Makiko Ohshima^a, Akihiko Taguchi^{a,b}, Yukiko Kasahara^b, Tomoaki Ikeda^c, Tomohiro Matsuyama^d

^a Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute, 5-7-1, Fujishiro-dai, Suita, Osaka, 565-8565, Japan

^b Department of Regenerative Medicine, Institute of Biomedical Research and Innovation, 2-2, Minami-machi, Minatojima, Chuo-ku, Kobe, 650-0047, Japan

^c Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan

^d Laboratory of Neurogenesis and CNS Repair, Institute for Advanced Medical Science, Hyogo College of Medicine, 1-1, Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan

ARTICLE INFO

Article history:

Received 18 January 2013

Revised 1 April 2013

Accepted 18 April 2013

Available online 4 May 2013

Keywords:

Neonatal stroke

Neonatal encephalopathy

Focal ischemia

Middle cerebral artery occlusion

Hypoxic–ischemic encephalopathy

CB-17 mouse

Variability

ABSTRACT

Neonatal stroke occurs in 1/4000 live births and leaves life-long neurological impairments, such as cerebral palsy and epilepsy. Currently, the rodent models of neonatal stroke that are available exhibit significant inter-animal variability, which makes it difficult to accurately assess the mechanisms of brain injury and the efficacy of candidate treatments. We aimed to introduce a novel, highly reproducible model of stroke, middle cerebral artery occlusion (MCAO), in immature mice, and to evaluate the reproducibility of this model compared with a conventional hypoxia–ischemia (HI) model. Postnatal day 12 CB-17 mice underwent left MCAO by direct electrocoagulation. The MCAO model exhibited excellent long-term survival; 85% up to 8 weeks after the insult. Infarct was evident in every animal with MCAO ($n = 27$) and was confined to the cortex, with the exception of some mild thalamic injury. While the % stroke volume 48 h after the insult was consistent in the MCAO group, range: 17.8–30.4% (minimum–maximum), it was substantially less consistent in the HI group, range: 3.0–70.1%. This contrasting variability between the two models was also evident in the cerebral blood flow, 24 h after the insult, and in the ipsilateral hemispheric volume, as assessed at 8 weeks after the insult. Mice with MCAO exhibited significant neurofunctional deficits in the rotarod and open-field tests. Preclinical studies for neonatal stroke could become more reliable using this model, with even a potential reduction in the number of pups required for statistical significance. The contrasting variability between the two models may provide insights into the factors that contribute to inter-animal variability in brain injury.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Perinatal/neonatal arterial ischemic stroke occurs in 1/2800 to 1/5000 live births, has a mortality rate of 2–10%, and leaves life-long neurological impairments, such as cerebral palsy, cognitive delay, and epilepsy (Chabrier et al., 2011; Golomb et al., 2006; Nelson and Lynch, 2004). The common early symptoms are seizures, persistently altered muscle tone, and decreased consciousness (Chabrier et al., 2011). Most perinatal arterial ischemic events occur in the region of the middle cerebral artery (MCA), with a left-hemisphere predominance (Lee et al., 2005; Sreenan

et al., 2000). While full-term infants tend to exhibit occlusion of the main branch, preterm infants tend to exhibit occlusions of a cortical branch or one or more of the lenticulostriate branches (de Vries et al., 1997). There is currently no evidence-based treatment for neonates with stroke (Chabrier et al., 2011). Furthermore, the average 5-year direct medical cost for neonatal stroke is approximately \$52,000 US (Gardner et al., 2010).

When investigating brain injuries, it is essential to utilize a highly reproducible model of brain injury. The model has to provide: 1) an accurate neurological evaluation, 2) a detailed evaluation of the injury/neuroprotection mechanisms, and 3) limitation in the numbers of animals used. Several neonatal stroke models have been developed using artery obstruction (Ashwal et al., 1995; Comi et al., 2004; Derugin et al., 1998; Mitsufuji et al., 1996; Renolleau et al., 1998; Wen et al., 2004). Almost all of these models exhibit significant inter-animal variability in the extent of the brain injury; i.e. a subset of pups exhibit no perceivable brain injury.

Neonatal encephalopathy (NE) is a neonatal neurological syndrome with clinical features that include decreased consciousness –

Abbreviations: MCA, middle cerebral artery; MCAO, middle cerebral artery occlusion; NE, neonatal encephalopathy; HIE, hypoxic–ischemic encephalopathy; HI, hypoxic–ischemic, hypoxia–ischemia; CBF, cerebral blood flow; ANOVA, analysis of variance.

* Corresponding author. Fax: +81 6 6835 5496.

E-mail addresses: tsuji.masahiro.ri@mail.ncvc.go.jp (M. Tsuji), oshima.makiko.ri@mail.ncvc.go.jp (M. Ohshima), taguchi@fbri.org (A. Taguchi), kasahara@fbri.org (Y. Kasahara), t-ikeda@clin.medic.mie-u.ac.jp (T. Ikeda), tomohiro@hyo-med.ac.jp (T. Matsuyama).

0014-4886/\$ – see front matter © 2013 Elsevier Inc. All rights reserved.
<http://dx.doi.org/10.1016/j.expneurol.2013.04.015>

usually associated with respiratory depression, altered muscle tone, disturbances of cranial nerve function – especially impaired feeding, and often seizures (Volpe, 2012). The most common etiology of NE is cerebral ischemia; hypoxic–ischemic encephalopathy (HIE) 50–80%, and stroke ~5–10% (Volpe, 2012), NE encompasses HIE and stroke. Recently, some authors have proposed that the term HIE should not be used in practice and should be replaced by the more general term, NE, for a number of reasons (Dammann et al., 2011), whereas other authors have opposed this proposal (Volpe, 2012). The most widely-used HIE model is the Rice–Vannucci model, which combines permanent unilateral ligation of the carotid artery in 7-day-old rat pups, along with exposure to hypoxia (Johnston et al., 2005; Rice et al., 1981). It is important to note that this model also exhibits significant inter-animal variability in the extent of the brain injury (Aden et al., 2002; Sheldon et al., 1998).

Some neonates with stroke can present signs and symptoms similar to HIE, and vice-versa. Moreover, some babies may exhibit both etiologies, and it is often difficult to isolate the cause of NE. Therefore, it is important to understand the differences between arterial ischemic stroke and hypoxia–ischemia (HI). Nevertheless, to the best of our knowledge, only one study (Ashwal et al., 2007) has directly compared the HI model in immature animals and a stroke model in immature animals to date.

We have previously developed a highly reproducible model of adult stroke induced by direct electrocoagulation of the unilateral MCA in CB-17 (CB-17/lcr-+/+Jcl) and SCID (CB-17/lcr-scid/scidJcl) mice (Taguchi et al., 2004, 2010). Recently, we adapted the same technique to immature CB-17 mice, and have succeeded in developing a model of neonatal stroke that shows remarkable consistency of the brain injury. The objectives of our study were: 1) to introduce a novel model of stroke in immature mice and 2) to test reproducibility of this model as compared to the HI model.

Methods

Animals and surgeries

Postnatal day 12 (P12) male and female CB-17 mouse pups ($n = 94$, weight: 6.7 ± 1.2 g) (CLEA Japan Inc., Tokyo, Japan) were prepared for surgery. P8–12 mice are considered comparable to human term (P0) neonates with regard to brain maturation (Hagberg et al., 2002). All experiments were performed in accordance with protocols approved by the Experimental Animal Care and Use Committee of the National Cerebral and Cardiovascular Center.

Permanent MCA occlusion (MCAO) was produced by a modification of the adult MCAO model that we have reported previously (Taguchi et al., 2010) (Fig. 1). A skin incision was made between the left eye and ear under isoflurane anesthesia (4.0% for induction, 1.5–2.0% for maintenance). The zygoma was dissected to visualize the MCA through the cranial bone. A hole was made in the temporal bone by removing a portion of it using fine forceps. The left MCA was electrocauterized, and disconnected just distal to its crossing of the olfactory tract (distal M1 portion). The average duration of the whole procedure was approximately 15 min. HI was induced by a combination of permanent occlusion of the left common carotid artery and exposure to 8% oxygen for 30 min in the P12 CB-17 mice, as described previously (Ohshima et al., 2012) (Fig. 1). Sham-surgery controls underwent open-skull surgery without MCA electrocoagulation. To properly assess the differences in variability between the two models, a single researcher, the first author, performed all surgical procedures. All analyses were performed by investigators who were blinded to the experimental group.




Fig. 1. Representation of the circle of Willis in rodents. The anatomic arterial system at the base of the brain in horizontal projection. ACA; anterior cerebral artery. BA; basilar artery. CCA; common carotid artery. MCA; middle cerebral artery. PCA; posterior cerebral artery. In the MCA occlusion model, the left MCA is permanently occluded (gray box). In the hypoxia–ischemia model, the left CCA is permanently occluded (open box) followed by transient systemic exposure to hypoxia.

Cerebral blood flow measurements

The cortical surface cerebral blood flow (CBF) was measured by a laser speckle flowmetry imaging system (Omegawave Inc., Tokyo, Japan) immediately before and 24 h after MCAO or HI, as described previously, with a minor modification (Ohshima et al., 2012). CBF was measured through the intact skull with an open-scalp.

Behavioral tests

Sensorimotor skills were evaluated 2 weeks after the insult (P26) using the rotarod test, as rodents with brain damage have been reported to exhibit behavioral impairment at this time point (Jansen and Low, 1996). The rotarod accelerated from 4 to 40 rpm over 5 min (Muromachi Kikai Co., Ltd., Tokyo, Japan). The time until the mouse fell off the rotating drum was recorded in 5 consecutive sessions, and the average time spent on the drum was used for statistical comparison.

Locomotor and exploratory behaviors were evaluated 5 weeks after the insults (almost 7 weeks of age) using the open-field test, as in our preliminary study mice began to respond to a dark environment from this age onward. Animals were allowed to search freely in a box (30 × 30 cm) for 30-min in a light environment and for the subsequent 30-min in a dark environment (Taiyo Electric Co., Ltd, Osaka, Japan). On the X-, Y-, and Z-banks of the open-field, infrared beams were mounted at specific intervals. The total number of beam crossings by the animal was counted and scored as “locomotion” for the horizontal movement, and as “rearing” for the vertical movement. Both behavioral tests were repeated one week before sacrifice at 8 weeks after the insult.

Histological analyses

Morphological evaluation of the brain injury was performed, as described previously (Tsuji et al., 2004, 2012). Forty-eight hours after the MCAO or HI insult, the brain was removed and sectioned coronally in 1-mm thick slices. The area of the viable ipsilateral and contralateral hemispheres, which stained red with 2,3,5-triphenyltetrazolium chloride (TTC) in each brain section, was measured using ImageJ software (NIH, Bethesda, USA). The hemispheric volume was estimated by integrating the hemispheric areas.

For longer-term evaluation, separate sets of animals were perfusion-fixed intracardially with 4% paraformaldehyde, 8 weeks after the insult. In assessing the hematoxylin–eosin-stained sections, neuropathological injury in the cerebral cortex was scored on a scale ranging from 0 to 4 points (0, no injury; 4, extensive confluent infarction). Neuropathologic injury in the hippocampus, striatum, and thalamus was scored on a scale ranging from 0 to 6 points. The ipsilateral and contralateral areas in the four regions and the corpus callosum were measured using ImageJ software. The ratios of the ipsilateral/contralateral areas in the five regions were calculated after summing the areas in four brain sections (cortex) or two brain sections (hippocampus, striatum, thalamus, and corpus callosum).

Statistics

The mortality rate of the animals was analyzed using Fisher's exact test with Bonferroni's correction for multiple comparisons. Hemispheric volumes, and CBF were assessed using two-way analysis of variance (ANOVA), followed by the Bonferroni test. The differences in body weight were assessed using one-way ANOVA, followed by the Bonferroni test. The injury scores were not distributed normally, so differences in injury scores were assessed with the Mann–Whitney *U* test. Ratios of the ipsilateral/contralateral areas were assessed using a Kruskal–Wallis test, followed by Dunn's multiple comparison, as the variances of the ratios were significantly different among the three groups. Pearson's product–moment correlation coefficient analysis was performed to determine the correlation between CBF and brain injury. Outcomes in the rotarod and open-field tests performed at two time points were assessed using two-way repeated measures ANOVA. Temporal changes during the course of a 60-min session in open-field test were then analyzed using two-way repeated measures ANOVA. Differences were considered significant at $P < 0.05$. The results are presented as the mean \pm standard deviation (SD), unless otherwise noted.

Results

Mortality and body weight

All pups that were prepared for surgery underwent the surgery successfully. Although some pups experienced bleeding during the MCAO surgery, all pups were included in the subsequent analyses. Survival was 100% at 48 h and 85% at 8 weeks after MCAO (Table 1). Body weights at P12 and 8 weeks later did not differ among groups, including the no-surgery controls (Table 2).

Table 1
Mortality rates.

	48 h-survival cohort	8-week-survival cohort
No-surgery		0/13
Sham-surgery		2/17
HI	1/12	6/22
MCAO	0/10	3/20

None of the pups died during the surgical procedure for either MCAO (middle cerebral artery occlusion) or HI (hypoxia–ischemia). In each cohort, mortality rates did not differ significantly between groups.

Table 2
Body weights.

	Postnatal day 12	8 weeks later
No-surgery	6.5 \pm 0.6	21.9 \pm 2.0
Sham-surgery	6.9 \pm 0.9	22.2 \pm 2.1
HI	6.6 \pm 1.4	20.5 \pm 2.3
MCAO	6.8 \pm 1.1	21.9 \pm 3.2

Body weights (grams) (mean \pm SD) at postnatal day 12 (the day of surgery) and 8 weeks later were not different between groups. MCAO; middle cerebral artery occlusion, HI; hypoxia–ischemia.

Morphological brain injury

Forty-eight hours after the insult, moderate–complete TTC discoloration was observed in all 10 pups that were subjected to MCAO, while discoloration was observed in only five out of 11 pups that were subjected to HI (Fig. 2A). The discoloration was confined to the ipsilateral cerebral cortex, and its location and size were consistent in all pups in the MCAO group, with the exception of one pup that exhibited discoloration extending to the striatum. In contrast, the location and size of the discoloration was markedly more variable in the HI group. The mean % stroke volume was 25.1 \pm 3.6% in the MCAO group and 15.5 \pm 18.6% in the HI group. The % stroke volume was calculated as follow: ((contralateral volume – viable ipsilateral volume) / contralateral volume) \times 100%. Variances of the viable ipsilateral hemispheric volume and % stroke volume differed significantly between the two models ($P < 0.001$) (Fig. 2B).

Eight weeks after the insult, all 17 mice with MCAO exhibited consistent macroscopic cortical damage (Fig. 2C). The mean ipsilateral hemispheric volume was 73.0 \pm 3.2 mm³ in the MCAO group, and 72.3 \pm 23.0 mm³ in the HI group (Fig. 2D). Of note, the sham-surgery group was not different from the no-surgery group, suggesting that the open-skull surgical procedure did not cause noticeable morphological damage. No sex differences in hemispheric volumes were observed at either time point in any of the groups.

Neuropathological injury scores in the four brain regions examined differed between the two models (Fig. 3A). The ratios of the ipsilateral/contralateral areas in the four regions and corpus callosum differed among the three groups including the sham-surgery group (Fig. 3B). Interestingly, in the MCAO group, most mice exhibited mild thalamic injury, in contrast with a virtual absence of striatal or hippocampal injury. Furthermore, the thalamic damage in the MCAO model was strictly restricted to the ipsilateral ventroposterior thalamic nuclei (VPN), which contained many pyknotic cells (Fig. 3C). In contrast, the thalamic injury in the HI model was variable in terms of its distribution and severity. In both models, the ipsilateral corpus callosum exhibited mild atrophy; however, this only reached statistical significance in the MCAO model.

CBF

The CBF was decreased in the MCA territory on the ipsilateral side in all pups 24 h after the HI or MCAO insult. The degree of the CBF reduction was consistent after MCAO, whereas it was variable between animals after HI (Figs. 4A, B). The CBF 24 h after the insult was compared with the morphological brain injury at 8 weeks after the insult (Fig. 4C). The reduction in CBF after the MCAO did not correlate with the subsequent morphological brain injury. In stark contrast, the reduction in CBF after the HI insult correlated strongly with brain injury ($R^2 = 0.99$), which is consistent with our previous report in P8 mice with the HI insult (Ohshima et al., 2012).

Rotarod performance

Sensorimotor performance, as assessed by rotarod treadmill at 2 and 7 weeks after the insult was analyzed by two-way repeated




Fig. 2. Macroscopic brain injuries. (A) Images of TTC-stained brain sections 48 h after middle cerebral artery occlusion (MCAO) or hypoxia–ischemia (HI). The brains with the mildest injury and the most severe injury in the MCAO group and those with the mildest, the average, and the most severe injury in HI group are shown. The brain injury was highly consistent after MCAO. In contrast, the brain injury varied substantially after HI (the arrow indicates a small area of discoloration). (B) Hemispheric volumes of viable tissue, which stained red, examined at 48 h after the insult (HI *n* = 11; MCAO *n* = 10). (C) Images of brain slices 8 weeks after the insult. (D) Hemispheric volumes examined at 8 weeks after the insult. † Significant difference in the variances between the groups (*P* < 0.001). There were no significant differences in the ipsilateral hemispheric volumes between the no-surgery and sham-surgery groups, nor in the contralateral hemispheric volumes in the no-surgery, sham-surgery group, and MCAO groups. (no-surgery *n* = 7; sham-surgery *n* = 15; HI *n* = 16; MCAO *n* = 17).




Fig. 3. Microscopic brain injuries. (A) Neuropathological injury scores examined in hematoxylin–eosin-stained sections 8 weeks after the insult. ****P* < 0.001. (HI *n* = 16; MCAO *n* = 17) (B) The ratios of ipsilateral/contralateral areas in each region examined at 8 weeks after the insult. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, compared with sham. Note the difference in the error bars (standard deviation) between the models (sham-surgery *n* = 7; HI *n* = 10; MCAO *n* = 10). Hipp; hippocampus. CC; corpus callosum. (C) Representative image of H&E-stained sections of mice brain 8 weeks after the MCAO. There is a clearly demarcated old infarct in the ipsilateral cortex. The ipsilateral thalamus is mildly atrophic. The labeled boxes indicate the regions that were selected for higher magnification (×20). Many pyknotic neurons are observed in the ipsilateral ventroposterior thalamic nucleus (VPN). The contralateral VPN appears normal.




Fig. 4. Cerebral blood flow. (A) Images of the cerebral blood flow (CBF) 24 h after the insult. The reduction of the CBF, indicated by the bluish color, was consistent after MCAO, but not after HI (the arrowheads indicate the main trunk of the MCA). (B) CBF levels were measured in the ischemic core region (the box with dotted line) of the MCA territory and in the matching region on the contralateral side before and after the insult. † Significant difference compared with the pre-surgery or sham-surgery groups ($P < 0.001$), and significant difference between each model ($P < 0.01$) (pre-surgery $n = 7$; sham-surgery $n = 8$; HI $n = 12$; MCAO $n = 17$). (C) The ratio of the ipsilateral CBF to the contralateral CBF at 24 h after the insult was compared with the ratio of the ipsilateral hemispheric volume to the contralateral hemispheric volume (assessed 8 weeks after the insult). The correlation between the degree of CBF reduction and the degree of brain damage is extremely strong in the HI group ($R^2 = 0.99$). (HI $n = 6$; MCAO $n = 7$).

measure ANOVA. There were significant time and group differences; the performance in mice with MCAO was significantly impaired compared with that in the sham-surgery group (Fig. 5). The impairment in the rotarod performance in mice with HI was not statistically significant.

Open-field activities

We initially analyzed overall activities during 60-min sessions at 5 and 7 weeks after the insult using two-way repeated measures ANOVA (Figs. 6A, B). While there was no time difference with respect to either locomotion or rearing, there was a significant group difference with respect to rearing, but not locomotion; mice with HI were hypoactive compared with the mice in the other three groups.




Fig. 5. Rotarod test. Repeated-measures two-way ANOVA showed significant time and group differences in sensorimotor performance, assessed 2 and 7 weeks after the insult. Performance was significantly impaired in mice with MCAO compared with the sham-surgery groups. * $P < 0.05$. (no-surgery $n = 19$; sham-surgery $n = 13$; HI $n = 16$; MCAO $n = 11$, 2 weeks after the insult. no-surgery $n = 9$; sham-surgery $n = 10$; HI $n = 13$; MCAO $n = 11$, 7 weeks after the insult).

There were no overall reductions in locomotion or rearing in the mice with MCAO.

We then analyzed the temporal changes throughout a 60-min session in 5-min increments using two-way repeated measures ANOVA. With respect to locomotion, the mice with MCAO did not respond to the change of environment from light to dark, whereas mice in all other groups became hyperactive in response to the dark environment, either at 5 weeks (data not shown) or 7 weeks after the insult (Fig. 6B). With respect to rearing, there were significant group differences at both 5 weeks (data not shown) and 7 weeks (Fig. 6C) after the insult. The mice with HI exhibited significantly less rearing compared with mice in all other groups.

Discussion

In this study, we have demonstrated that permanent occlusion of the MCA in CB-17 mice induces a highly reproducible and selective cortical infarction. We believe that our model has clinical relevance to, at least a portion of infants with stroke, as an isolated large infarct in the vascular territory of left MCA is most commonly observed in infants with stroke (Lee et al., 2005; Sreenan et al., 2000). This high degree of consistency allows the effective screening of various experimental treatments using smaller numbers of animals. The most important point in achieving this high reproducibility is the use of the CB-17 strain, which exhibits very little variation in the cerebral vascular structure (Taguchi et al., 2010). It is known that the degree of brain damage and its reproducibility in neonatal rodent models of HI and stroke are dependent upon the strain used (Comi et al., 2005; Sheldon et al., 1998). In addition to the high reproducibility, the advantages of our model are its simple procedure and high long-term survival, which provides the opportunity for long-term evaluation of neuropathological and functional outcomes. Indeed, our model exhibited significant long-term neurofunctional deficits.




Fig. 6. Open-field test. (A, B) Overall activities during the 60-min session 5 and 7 weeks after the insult were analyzed by two-way repeated measures ANOVA. While there was no time difference with respect to either locomotion or rearing, there were significant group differences with respect to rearing, but not locomotion; mice with HI were significantly hypoactive compared with mice in the other three groups. (no-surgery $n = 14$; sham-surgery $n = 10$; HI $n = 16$; MCAO $n = 14$, 5 weeks after the insult. no-surgery $n = 13$; sham-surgery $n = 11$; HI $n = 16$; MCAO $n = 13$, 7 weeks after the insult). (C, D) Temporal changes in 5-min increments were analyzed by repeated-measures two-way ANOVA. There were significant group differences with respect to locomotion at 7 weeks after the insult. Mice in the MCAO group were significantly hypoactive during the first 5-min period in the dark than mice in the HI group. $\S P < 0.05$. There were significant increases in the activity from the last 5-min period in the light environment to the first period in the dark environment in all groups except for the MCAO group. $**P < 0.01$. With respect to rearing, there were significant group differences at 7 weeks. Mice in the HI group exhibited significantly less rearing activity. $\S P < 0.05$, compared with MCAO group, $\dagger P < 0.05$, compared with the no-surgery, sham-surgery and MCAO groups. Mean \pm SEM.

Six models of neonatal stroke using artery obstruction have been developed (Ashwal et al., 1995, 2007; Bonnin et al., 2011; Comi et al., 2004; Derugin et al., 1998, 2000; Mitsufuji et al., 1996; Renolleau et al., 1998; Wen et al., 2004), and are summarized in Table 3. All models, except one, exhibit obvious inter-animal variability; some of the animals subjected to the insult do not develop infarct, as is the case in the HI model. In a permanent MCAO model developed by Wen et al. (2004), in which a tailor-made intraluminal suture embolus was placed in P7 SD rats, infarct was noted in all 10 pups that were subjected to the insult. However, the long-term survival was not reported. Taken together, among the currently available rodent

models of neonatal stroke our model exhibits the highest reproducibility with excellent long-term survival. Nevertheless, those models, including ours, should be complementary, in order to lead to new understanding of the mechanisms of neonatal stroke and to find therapies for neonatal stroke. Our model has some weaknesses compared with other models. Firstly, this model does not utilize a reperfusion phase. Reperfusion may or may not occur in some patients, or the reperfusion may occur too late to activate its downstream events in other patients. Secondly, increasing or decreasing the degree of brain injury is not possible in this model. Thirdly, craniotomy results in stress to the animal and trauma to local tissues, even though the present study

Table 3
Immature rodent models of cerebral ischemia.

	Method of obstruction	Age and Species/strain	Ratio of infarct formation*	Long-term survival	Author and reference
1	t-f-MCAO	P14-18 or P10 SH rats	8/9	21% by 28 days	Ashwal et al., 1995, 2007
2	t-f-MCAO	P7 Sprague-Dawley rats	8/10, 20/31	71% by 7 days	Derugin et al., 1998, 2000
3	p-CCAO + t-CCAO†	P10 Wistar rats	NA	NA	Mitsufuji et al., 1996
4	p-MCAO + t-CCAO‡	P7 Wistar rats	10/10, 36/66	NA	Renolleau et al., 1998; Bonnin et al., 2011
5	p-CCAO	P12 CD1 mice	20/28	86% by 7 days	Comi et al., 2004
6	p-f-MCAO	P7 SD rats	10/10	NA	Wen et al., 2004
Present study	p-MCAO	P12 CB-17 mice	27/27	85% by 8 weeks	

These are unilateral cerebral ischemia models, unless otherwise noted. t-; transient. f-; intraluminal filament. p-; permanent. MCAO; middle cerebral artery occlusion. CCAO; common carotid artery occlusion. P; postnatal day. SH; spontaneously hypertensive. NA; not available. * Ratio of the number of animals presenting with obvious infarct to the number of animals that survived until the time of assessment. † Unilateral p-CCAO combined with contralateral t-CCAO. ‡ Unilateral MCAO by electrocoagulation combined with ipsilateral t-CCAO.

demonstrated that sham-surgery operated mice were not different from the no-surgery control mice, with respect to brain morphology, CBF, and behavior.

The differences in the variability between the two models (i.e., MCAO and HI) demonstrated in our study can provide insights into the mechanisms that lead to extensively variable susceptibility to HI insult by animals, even within littermates. The pivotal cause of the variation remains poorly understood. A number of explanations have been proposed for inter-animal variations in the extent of brain damage; 1) differences in collateral arteries in the brain (Rubino and Young, 1988), 2) the existence of several major MCA branching patterns (Rubino and Young, 1988), 3) subtle differences in the genetic background, 4) blood sugar level differences, which may result from variations in feeding times and amount (Chen et al., 2011; Hattori and Wasterlain, 1990), 5) temperature variation, 6) weight variation (Menzies et al., 1992), and 7) long surgery time and duration of isoflurane exposure (Chen et al., 2011). Our contrasting results in the two models suggest that these explanations are unlikely, because only the HI model exhibited substantial variability, despite the fact that all the aforementioned factors were consistent for both the MCAO and HI models. We cannot exclude the possibility that structural and physiological variations in the circle of Willis could contribute to the inconsistent brain damage after HI. Bonnin et al. (2011) reported that establishment of collateral recruitment via the basilar artery led to the presence or absence of a lesion. We also cannot exclude other possibilities, such as differences in the susceptibility to reperfusion damage, or in cardiovascular and respiratory function. As our model and the above-mentioned reproducible stroke model (Wen et al., 2004) are both permanent occlusion models, some mechanisms that occur during reperfusion may lead to large inter-animal variability.

There has only been one previous study in the literature that directly compared the MCAO and HI models (Ashwal et al., 2007). Unlike ours, variability in brain injury did not appear to be different between the two models in the previous study. The discrepancy between their results and ours may be due to the different MCAO procedures and the animals used. The previous report used a transient MCAO model in P10 spontaneously hypertensive rats, whereas we used a permanent MCAO model in P12 CB-17 mice.

We observed thalamic damage that was confined to the ipsilateral VPN in our MCAO model. As the VPN is supplied by thalamo-perforating arteries originating from the basilar artery systems (Oscar and Holschneider, 2012), MCAO does not cause direct ischemic injury to this nucleus. Secondary neuronal damage in the thalamic nuclei after focal ischemia has been reported in adult rat models (Dihne et al., 2002; Schroeter et al., 2006). The damage in VPN was possibly due to retrograde degeneration of the thalamocortical projection (Dihne et al., 2002). Thalamic atrophy has been seen in children with neonatal MCA infarct (Giroud et al., 1995).

Our MCAO model exhibited neurological dysfunction in the rotarod and open-field tests; the mice with MCAO lost the response to a change of the environment from light to dark, while their overall activities were not disturbed significantly. The results in behavioral tests in immature rodent models of stroke or HI are not consistent and can often be contradictory. Rodents with ischemic insult exhibited significantly poorer rotarod performance compared with controls in some (Chen et al., 2012; Jansen and Low, 1996), but not all studies (Aden et al., 2003; Kadam et al., 2009; Lubics et al., 2005). Similarly, rodents with ischemic insult exhibited altered behavior in open-field test in some studies (Aden et al., 2002; Kadam et al., 2009; Lubics et al., 2005), but not in others (de Paula et al., 2009). The discrepancies among the reports may be due to differences in species/strain (de Visser et al., 2006), in the extent of brain damage, in the timing of the assessment (Lubics et al., 2005), and in the experimental paradigm. In the future more sensitive measures will be needed to confirm these results.

Seizure behavior, which is one of the main presenting symptoms in neonates with stroke, was not observed in our model during the 2-hour period following artery occlusion. Seizure behavior has been reported in a stroke model in immature CD1 mice (Comi et al., 2004), but not in other stroke models in immature rodents. That is likely due to strain-related differences in the susceptibility to seizures (Comi et al., 2005) or simply due to a lack of detailed assessment for seizure activities in the models. One possible reason to explain the inability to cause seizure in our model would be the distribution of the brain injury, which is confined to the ipsilateral cortex and did not involve the hippocampus. More detailed and longer observation periods will be needed before we can conclude that our model does not cause seizure activity, as the median time to seizure after the insult can be more than 2 h in some strains (Comi et al., 2005).

Conclusions

We believe that this model is useful for detailed analyses in preclinical studies of neonatal stroke using a smaller number of animals, because of its high reproducibility, excellent long-term survival rate, and measurable neurofunctional deficits, and that this model will be useful in assessing functional improvement in response to experimental therapies.

Disclosures

None.

Sources of funding

This work was funded by a Grant-in-Aid for Scientific Research (JSPS KAKENHI 24591617) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Acknowledgments

We thank Manami Sone for excellent technical assistance. We also thank Kenichi Mishima, Ph.D., Masafumi Ihara, M.D., and Kenichi Yamahara M.D. for helpful discussions.

References

- Aden, U., Dahlberg, V., Fredholm, B.B., Lai, L.J., Chen, Z., Bjelke, B., 2002. MRI evaluation and functional assessment of brain injury after hypoxic ischemia in neonatal mice. *Stroke* 33, 1405–1410.
- Aden, U., Halldner, L., Lagercrantz, H., Dalmau, I., Ledent, C., Fredholm, B.B., 2003. Aggravated brain damage after hypoxic ischemia in immature adenosine a2a knockout mice. *Stroke* 34, 739–744.
- Ashwal, S., Cole, D.J., Osborne, S., Osborne, T.N., Pearce, W.J., 1995. A new model of neonatal stroke: reversible middle cerebral artery occlusion in the rat pup. *Pediatr. Neurol.* 12, 191–196.
- Ashwal, S., Tone, B., Tian, H.R., Chong, S., Obenaus, A., 2007. Comparison of two neonatal ischemic injury models using magnetic resonance imaging. *Pediatr. Res.* 61, 9–14.
- Bonnin, P., Leger, P.L., Deroide, N., Fau, S., Baud, O., Pocard, M., Charriaut-Marlangue, C., Renolleau, S., 2011. Impact of intracranial blood-flow redistribution on stroke size during ischemia-reperfusion in 7-day-old rats. *J. Neurosci. Methods* 198, 103–109.
- Chabrier, S., Husson, B., Dinomais, M., Landrieu, P., Nguyen The Tich, S., 2011. New insights (and new interrogations) in perinatal arterial ischemic stroke. *Thromb. Res.* 127, 13–22.
- Chen, H., Burris, M., Fajilan, A., Spagnoli, F., Tang, J., Zhang, J.H., 2011. Prolonged exposure to isoflurane ameliorates infarction severity in the rat pup model of neonatal hypoxia-ischemia. *Transl. Stroke Res.* 2, 382–390.
- Chen, H., Spagnoli, F., Burris, M., Rolland, W.B., Fajilan, A., Dou, H., Tang, J., Zhang, J.H., 2012. Nanoerythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia and ischemia. *Stroke* 43, 884–887.
- Comi, A.M., Weisz, C.J., Highet, B.H., Johnston, M.V., Wilson, M.A., 2004. A new model of stroke and ischemic seizures in the immature mouse. *Pediatr. Neurol.* 31, 254–257.
- Comi, A.M., Johnston, M.V., Wilson, M.A., 2005. Strain variability, injury distribution, and seizure onset in a mouse model of stroke in the immature brain. *Dev. Neurosci.* 27, 127–133.

- Dammann, O., Ferriero, D., Gressens, P., 2011. Neonatal encephalopathy or hypoxic-ischemic encephalopathy? Appropriate terminology matters. *Pediatr. Res.* 70, 1–2.
- de Paula, S., Vitola, A.S., Greggio, S., de Paula, D., Mello, P.B., Lubianca, J.M., Xavier, L.L., Fiori, H.H., Dacosta, J.C., 2009. Hemispheric brain injury and behavioral deficits induced by severe neonatal hypoxia-ischemia in rats are not attenuated by intravenous administration of human umbilical cord blood cells. *Pediatr. Res.* 65, 631–635.
- de Visser, L., van den Bos, R., Kuurman, W.W., Kas, M.J., Spruijt, B.M., 2006. Novel approach to the behavioural characterization of inbred mice: automated home cage observations. *Genes Brain Behav.* 5, 458–466.
- de Vries, L.S., Groenendaal, F., Eken, P., van Haastert, I.C., Rademaker, K.J., Meiners, L.C., 1997. Infarcts in the vascular distribution of the middle cerebral artery in preterm and fullterm infants. *Neuropediatrics* 28, 88–96.
- Derugin, N., Ferriero, D.M., Vexler, Z.S., 1998. Neonatal reversible focal cerebral ischemia: a new model. *Neurosci. Res.* 32, 349–353.
- Derugin, N., Wendland, M., Muramatsu, K., Roberts, T.P., Gregory, G., Ferriero, D.M., Vexler, Z.S., 2000. Evolution of brain injury after transient middle cerebral artery occlusion in neonatal rats. *Stroke* 31, 1752–1761.
- Dihne, M., Grommes, C., Lutzenburg, M., Witte, O.W., Block, F., 2002. Different mechanisms of secondary neuronal damage in thalamic nuclei after focal cerebral ischemia in rats. *Stroke* 33, 3006–3011.
- Gardner, M.A., Hills, N.K., Sidney, S., Johnston, S.C., Fullerton, H.J., 2010. The 5-year direct medical cost of neonatal and childhood stroke in a population-based cohort. *Neurology* 74, 372–378.
- Giroud, M., Fayolle, H., Martin, D., Baudoin, N., Andre, N., Gouyon, J.B., Nivelon, J.L., Dumas, R., 1995. Late thalamic atrophy in infarction of the middle cerebral artery territory in neonates. A prospective clinical and radiological study in four children. *Childs Nerv. Syst.* 11, 133–136.
- Golomb, M.R., Cvijanovich, N.Z., Ferriero, D.M., 2006. Neonatal brain injury. In: Swaiman, K.F., Ashwal, S., Ferriero, D.M. (Eds.), *Pediatric neurology, principles & practice*, 4th ed. Mosby Elsevier, Philadelphia, pp. 329–343.
- Hagberg, H., Peebles, D., Mallard, C., 2002. Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults. *Ment. Retard. Dev. Disabil. Res. Rev.* 8, 30–38.
- Hattori, H., Wasterlain, C.G., 1990. Posthypoxic glucose supplement reduces hypoxic-ischemic brain damage in the neonatal rat. *Ann. Neurol.* 28, 122–128.
- Jansen, E.M., Low, W.C., 1996. Long-term effects of neonatal ischemic-hypoxic brain injury on sensorimotor and locomotor tasks in rats. *Behav. Brain Res.* 78, 189–194.
- Johnston, M.V., Ferriero, D.M., Vannucci, S.J., Hagberg, H., 2005. Models of cerebral palsy: which ones are best? *J. Child Neurol.* 20, 984–987.
- Kadam, S.D., Mulholland, J.D., Smith, D.R., Johnston, M.V., Comi, A.M., 2009. Chronic brain injury and behavioral impairments in a mouse model of term neonatal strokes. *Behav. Brain Res.* 197, 77–83.
- Lee, J., Croen, L.A., Lindan, C., Nash, K.B., Yoshida, C.K., Ferriero, D.M., Barkovich, A.J., Wu, Y.W., 2005. Predictors of outcome in perinatal arterial stroke: a population-based study. *Ann. Neurol.* 58, 303–308.
- Lubics, A., Reglodi, D., Tamas, A., Kiss, P., Szalai, M., Szalontay, L., Lengvari, I., 2005. Neurological reflexes and early motor behavior in rats subjected to neonatal hypoxic-ischemic injury. *Behav. Brain Res.* 157, 157–165.
- Menzies, S.A., Hoff, J.T., Betz, A.L., 1992. Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. *Neurosurgery* 31, 100–106.
- Mitsufuji, N., Yoshioka, H., Okano, S., Nishiki, T., Sawada, T., 1996. A new model of transient cerebral ischemia in neonatal rats. *J. Cereb. Blood Flow Metab.* 16, 237–243.
- Nelson, K.B., Lynch, J.K., 2004. Stroke in newborn infants. *Lancet Neurol.* 3, 150–158.
- Ohshima, M., Tsuji, M., Taguchi, A., Kasahara, Y., Ikeda, T., 2012. Cerebral blood flow during reperfusion predicts later brain damage in a mouse and a rat model of neonatal hypoxic-ischemic encephalopathy. *Exp. Neurol.* 233, 481–489.
- Oscar, U., Holschneider, D.P., 2012. Vascular supply. In: Watson, C., Paxinos, G., Puelles, L. (Eds.), *The Mouse Nervous System*. Academic Press, London, pp. 459–472.
- Renolleau, S., Aggoun-Zouaoui, D., Ben-Ari, Y., Charriaut-Marlangue, C., 1998. A model of transient unilateral focal ischemia with reperfusion in the p7 neonatal rat: morphological changes indicative of apoptosis. *Stroke* 29, 1454–1460.
- Rice III, J.E., Vannucci, R.C., Brierley, J.B., 1981. The influence of immaturity on hypoxic-ischemic brain damage in the rat. *Ann. Neurol.* 9, 131–141.
- Rubino, G.J., Young, W., 1988. Ischemic cortical lesions after permanent occlusion of individual middle cerebral artery branches in rats. *Stroke* 19, 870–877.
- Schroeter, M., Zickler, P., Denhardt, D.T., Hartung, H.P., Jander, S., 2006. Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. *Brain* 129, 1426–1437.
- Sheldon, R.A., Sedik, C., Ferriero, D.M., 1998. Strain-related brain injury in neonatal mice subjected to hypoxia-ischemia. *Brain Res.* 810, 114–122.
- Sreenan, C., Bhargava, R., Robertson, C.M., 2000. Cerebral infarction in the term newborn: clinical presentation and long-term outcome. *J. Pediatr.* 137, 351–355.
- Taguchi, A., Soma, T., Tanaka, H., Kanda, T., Nishimura, H., Yoshikawa, H., Tsukamoto, Y., Iso, H., Fujimori, Y., Stern, D.M., Naritomi, H., Matsuyama, T., 2004. Administration of CD34⁺ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. *J. Clin. Invest.* 114, 330–338.
- Taguchi, A., Kasahara, Y., Nakagomi, T., Stern, D.M., Fukunaga, M., Ishikawa, M., Matsuyama, T., 2010. A reproducible and simple model of permanent cerebral ischemia in CB-17 and SCID mice. *J. Exp. Stroke Transl. Med.* 3, 28–33.
- Tsuji, M., Wilson, M.A., Lange, M.S., Johnston, M.V., 2004. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. *Exp. Neurol.* 189, 58–65.
- Tsuji, M., Taguchi, A., Ohshima, M., Kasahara, Y., Ikeda, T., 2012. Progesterone and allopregnanolone exacerbate hypoxic-ischemic brain injury in immature rats. *Exp. Neurol.* 233, 214–220.
- Volpe, J.J., 2012. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. *Ann. Neurol.* 72, 156–166.
- Wen, T.C., Rogido, M., Gressens, P., Sola, A., 2004. A reproducible experimental model of focal cerebral ischemia in the neonatal rat. *Brain Res. Brain Res. Protoc.* 13, 76–83.

OBSTETRICS

Risk factors for maternal and fetal outcome in pregnancy complicated by Ebstein anomaly

Shinji Katsuragi, MD; Chizuko Kamiya, MD; Kaoru Yamanaka, MD; Reiko Neki, MD; Takekazu Miyoshi, MD; Naoko Iwanaga, MD; Chinami Horiuchi, MD; Hiroaki Tanaka, MD; Jun Yoshimatsu, MD; Koichiro Niwa, MD; Tomoaki Ikeda, MD

OBJECTIVE: The goal of the study was to examine risks in pregnancy in patients with Ebstein anomaly.

STUDY DESIGN: Data were examined retrospectively for 13 patients (27 pregnancies, 21 live births) with Ebstein anomaly during pregnancy who were treated at our institution from 1985 to 2011. The associated anomalies in these patients were atrial septal defect (ASD) ($n = 4$) and the Wolff-Parkinson-White syndrome ($n = 6$).

RESULTS: Before pregnancy, 2 patients underwent ASD closure and 1 received tricuspid valve replacement (TVR). In all patients, the cardiothoracic ratio increased from 55.1 at conception to 57.0 during pregnancy and 58.0 postpartum ($P < .05$). Cesarean sections were performed in 3 cases: 1 with ventricular tachycardia and orthopnea (New York Heart Association [NYHA] III) preterm; at full term, and the third in a patient with a mechanical tricuspid valve who developed

maternal cerebellum hemorrhage at 27 weeks. The baby died of prematurity in the third case. In all other cases (20 of 21), neonatal prognoses were good without congenital heart diseases. There were 6 spontaneous abortions. Recurrent paroxysmal supraventricular tachycardia occurred during pregnancy in 2 cases and was treated with adenosine triphosphate or verapamil. In 17 pregnancies, NYHA remained in class I and all had full-term vaginal delivery.

CONCLUSION: Maternal and fetal outcomes are good in patients with Ebstein anomaly and NYHA class I. However, pregnancy in Ebstein anomaly can be complicated with tachyarrhythmia or cardiac failure. In post-TVV cases, meticulous care is required for these complications during pregnancy and delivery.

Key words: arrhythmia, cardiac function, Ebstein anomaly, New York Heart Association, pregnancy

Cite this article as: Katsuragi S, Kamiya C, Yamanaka K, et al. Risk factors for maternal and fetal outcome in pregnancy complicated by Ebstein anomaly. *Am J Obstet Gynecol* 2013;209:452.e1-6.

Ebstein anomaly occurs in about 0.5% of cases of congenital heart disease.¹⁻⁴ This congenital malformation is characterized by downward displacement of tricuspid valve into the right ventricle because of an anomalous attachment of septal and posterior leaflets. The abnormally situated tricuspid orifice divides the right ventricle into a proximal atrialized segment and a distal functional small

ventricular chamber. Ebstein anomaly usually revealed tricuspid regurgitation with right atrial enlargement and is often associated with atrial septal defect (ASD) and the Wolff-Parkinson-White (WPW) syndrome type that leads to cyanosis and arrhythmias such as supraventricular tachyarrhythmia.³

Many women with Ebstein anomaly reach child-bearing age, but there is little information about the risks of pregnancy and delivery,⁵⁻⁷ with only 2 reports of a relatively large series of pregnancy complicated with Ebstein anomaly.^{7,8}

In these reports, there were a total of 56 patients and 153 pregnancies, in which miscarriage occurred in 16%, neonatal death in 2%, preeclampsia in 1%, preterm delivery in 29%, vaginal delivery in 90%, heart failure of New York Heart Association (NYHA) class III or above in 0.7%, and life-threatening arrhythmia in 0.7%.^{7,8} Thus, pregnancy in women with Ebstein anomaly is generally well tolerated, but some patients are undiagnosed until the onset of

symptoms such as dyspnea and atrial flutter in the latter half of the pregnancy.^{5,8} Furthermore, some patients with Ebstein anomaly are asymptomatic, even after multiple deliveries, and the condition may not be diagnosed until the age of 50 years or later.⁸

The variety of symptoms and disease severity and differences in complications such as cyanosis, arrhythmia, and stroke make a uniform evaluation difficult. Therefore, the current retrospective study of pregnancy complicated with Ebstein anomaly was carried out to determine factors that influence maternal and fetal prognosis.

MATERIALS AND METHODS

Maternal and fetal mortality and morbidity in 13 patients with Ebstein anomaly (27 pregnancies) were examined as a case series based on charts in our hospital from January 1985 to December 2011. Cases associated with congenital heart diseases other than ASD and patent foramen ovale were excluded.

From the Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Osaka (all authors except Dr Niwa), and the Department of Cardiology, St Luke's International Hospital, Tokyo (Dr Niwa), Japan.

Received April 12, 2013; revised June 2, 2013; accepted July 1, 2013.

The authors report no conflict of interest.

Reprints: Shinji Katsuragi, MD, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. skatsura12@yahoo.co.jp.

0002-9378/\$36.00

© 2013 Mosby, Inc. All rights reserved.

http://dx.doi.org/10.1016/j.ajog.2013.07.005

TABLE 1
Patient characteristics

Case	Associated lesions	Age at onset, mo	Age at initial diagnosis, mo	Age at delivery, y
1		9	9	25
2	ASD	3	5	35, 37
3	ASD WPW	5	26	35
4	ASD	6	28	31
5		6	10	28
6	ASD	7	7	30, 33
7	WPW	7	35	35, 39
8	WPW	18	38	38
9	WPW	10	10	31
10	WPW	13	21	25, 29
11	WPW	22	22	26, 28, 36
12		25	25	27, 36
13		30	30	32, 36

Each age except 9 months (case 1) is shown by age in years. In case 1, the first symptom was heart murmur.

ASD, atrial septal defect; WPW, Wolff-Parkinson-White syndrome.


Katsuragi. Ebstein anomaly in pregnancy. *Am J Obstet Gynecol* 2013.

Cardiac function was evaluated by echocardiography performed before pregnancy, at conception, in each trimester, and postpartum. Cardiothoracic ratio (CTR) was measured on chest X-rays taken before pregnancy, in the third trimester, postpartum, and at other times if needed. A Holter electrocardiogram was recorded in each trimester and postpartum. Vaginal delivery was attempted for women with spontaneous labor, whereas cesarean section was selected for those with a need for early delivery for both fetal and maternal indications. The NYHA classification was used to evaluate cardiac status.⁹

Data collection

Data were collected for maternal age; age at diagnosis; CTR; grade of tricuspid valve regurgitation (TR); NYHA functional class during and after pregnancy; delivery mode (cesarean section or vaginal delivery); treatment before, during, and after delivery; time of delivery (gestational weeks); and birthweight. Echocardiography was performed for all babies to evaluate associated congenital heart diseases.

FIGURE 1
Time of delivery and birthweight



A, The median (range) gestational weeks at delivery was 37.9 weeks (range, 27–39.4 weeks). Most cases delivered between 37 and 40 weeks, but 2 cases ended in preterm delivery at 27 and 28 gestational weeks. The number on the bar indicates the number of cases. **B**, The median (range) neonatal birthweight was 2664 g (1063–3590 g). Most cases were included in the standard normal distribution between 2000 and 4000 g, but in 2 cases the birthweight was less than 1500 g.

Katsuragi. Ebstein anomaly in pregnancy. *Am J Obstet Gynecol* 2013.

Statistical analysis

For continuous variables, a Student *t* test was performed for analysis of normally distributed data; otherwise a Wilcoxon test was used. All statistical analyses were performed using JMP 7 (SAS Institute, Cary, NC). *P* < .05 was considered statistically significant.

RESULTS

There were 27 pregnancies and 21 live births in 13 patients during the study period. Six pregnancies were spontaneously aborted before 10 weeks of gestation. The median (range) ages at the time of initial symptoms, diagnosis of Ebstein anomaly, and delivery were 10 (0–30), 21 (0–38), and 32 (25–29) years old, respectively (Table 1). In 2 patients, heart disease was not diagnosed at the time of conception (cases 7 and 8). Four patients had ASD, 6 had WPW syndrome, and 1 had both of these conditions. No patients had cyanosis.

The patients with ASD developed symptoms of Ebstein anomaly earlier than those with WPW (5.3 vs 11.2 years

old, $P < .05$), but there was no difference in the age of diagnosis (12.2 vs 10.2 years old, $P =$ not significant) or delivery (33.5 vs 32.2 years old, $P =$ not significant). The median time of delivery was 37.9 (27–39.4) gestational weeks, and the neonatal weight was 2664 (1063–3590) g (Figure 1). There were 2 early deliveries at 27 and 28 weeks, respectively, and in these 2 cases, the babies were extremely low birthweight infants (between 1000 and 1499 g) (Figure 1). There was 1 small-for-gestational-age baby. The other 20 babies were appropriate for gestational age. No babies had congenital heart diseases. One baby born with a birthweight of 1063 g at 27 weeks died of prematurity. All other babies showed normal growth and no neurological disability.

Treatment before pregnancy

Ablation therapy for paroxysmal supraventricular tachycardia (PSVT) accompanied with WPW syndrome) was performed in 2 cases before pregnancy (cases 9 and 11) (Table 2), and there was no other arrhythmia event during and after delivery. One patient (case 2) with mechanical tricuspid valve replacement (TVR) developed maternal cerebral hemorrhage at 27 weeks of gestation and cesarean section was performed.

Treatment during pregnancy

Nonsustained ventricular tachycardia (NSVT) was terminated with bisoprolol fumarate (case 1). Diuretics and oxygen were administered when dyspnea caused by cardiac failure occurred (cases 1 and 3) (Table 2). Two patients had recurrent PSVT during pregnancy (cases 7 and 10). Each arrhythmia was treated effectively with verapamil or adenosine triphosphate. Each patient underwent ablation therapy after delivery.

Treatment after delivery

The patient with ASD and severe TR (case 4) developed cardiac failure (NYHA class worsened to III) at 16 years after delivery, and ASD closure and tricuspid valvoplasty were performed (Table 2). In 2 cases, diuretics were given because of worsening of cardiac failure (cases 6 and 12).

TABLE 2
Treatment before, during, and after pregnancy

Case	TR before pregnancy	CTR (%) in 1st pregnancy			Delivery week	CV event	Treatment before pregnancy
		Before	Third	Post			
2	Mild	53	27	58	27	CHF	ASD closure, TVR (3 y)
9	Mild	46	39	53	39	PSVT	Ablation (15 y)
11	Mild	42	39	52	39	PSVT	Ablation (22 y)
During pregnancy							
1	Mod	62	28	66	28	CHF	Furosemide, oxygen
3	Mod	58	37	58	37	CHF	Furosemide, oxygen
7	Mod	nd	39	62	39	PSVT	Verapamil
10	Mild	47	39	55	39	PSVT	ATP
After pregnancy							
4	Sev	55	37	62	37	CHF	ASD closure, TVP
6	Mod	59	37	58	37	CHF	Furosemide
12	Sev	62	37	61	37	CHF	Furosemide
5	Mod	54	38	52	38	No	None
8	Mod	55	38	58	38	No	None
13	Mod	57	61	58	37	No	None

Furosemide; Bristol Laboratories, Luton, UK.

ASD, atrial septal defect; ATP, adenosine triphosphate; CHF, congestive heart failure; CV, cardiovascular; mod, moderate; PSVT, paroxysmal supraventricular tachycardia; sev, severe; TVP, tricuspid valvoplasty; TVR, tricuspid valve replacement.

Katsuragi. Ebstein anomaly in pregnancy. *Am J Obstet Gynecol* 2013.

Change in CTR

The median (range) CTR significantly increased from before to during pregnancy (55.1% [42–62%] vs 57.0% [51–72%], $P < .05$) and from before pregnancy to after delivery (55.1% [42–62%] vs 58.0% [52–62%], $P < .05$) (Figure 2).

Changes in TR

TR was severe in 3, moderate in 10, and trivial to mild in 8 pregnancies and did not change in any of the 21 cases throughout the study period. Enlargement of CTR greater than 0.6 during pregnancy and postpartum was more common in cases with moderate (8 of 10, 80%) and severe (3 of 3, 100%) TR, compared with mild TR cases (0 of 8, 0%).

Changes in NYHA functional class


In 18 of the 21 pregnancies, NYHA class I was maintained throughout pregnancy (Figure 3). In 17 of these pregnancies,

full-term vaginal delivery was possible. The other case was terminated at 27 weeks because of maternal cerebellum hemorrhage (case 2). One case with severe TR and ASD deteriorated in cardiac function from NYHA class I to III 16 years after delivery (case 4). Two cases dropped by 1 NYHA class (1 with class I, the other with class II) temporarily during pregnancy but returned to the original classes after delivery (cases 3 and 1).

COMMENT

We investigated the maternal and fetal outcomes in 21 pregnancies in 13 patients with Ebstein anomaly. There were 2 preterm cesarean sections and 1 neonatal death. Postdelivery courses were good, but 1 case with severe TR and ASD deteriorated in cardiac function from NYHA class I to III, and another patient with a severely enlarged right heart remained in class II but with transient deterioration to class III during pregnancy. Two patients needed diuretics

FIGURE 2
Changes in the cardiothoracic ratio



The median (range) of cardiothoracic ratios at conception, during pregnancy, and postpartum were 55.1% (46–62%), 57.0% (51–72%), and 58% (52–68%), respectively. The asterisk indicates a value of $P < .05$ (the Wilcoxon test) for conception vs during pregnancy and for conception vs postpartum.

Katsuragi. Ebstein anomaly in pregnancy. *Am J Obstet Gynecol* 2013.

postpartum because of worsening of edema. One patient transiently deteriorated to NYHA class II during pregnancy.

Maternal cyanotic congenital heart disease has been associated with prematurity and low birthweight and with infant survival rates of 50–55%.^{10–12} In the current study, there were 3 pregnancies in 2 patients with unrepaired ASD, but neither patient was cyanotic and the mother did not have hypoxemia. One fetus showed intrauterine growth restriction that was not related to maternal cyanosis. Obstetric complications were infrequent in this series and no patient had preeclampsia. The miscarriage rate of 21% was similar to the standard rate of 15–20%.^{13,14}

During pregnancy cardiac output increases to 150% with increased heart rate, and the autonomic nerve system is activated.¹⁵ These changes increase the risk of cardiac failure in patients with Ebstein anomaly because of superimposition of hyperdynamic and hypervolemic

circulatory stress on the preexisting enlarged right heart, decreased right ventricular function with increased TR, and a compressed left ventricle. The median CTR significantly increased during pregnancy and postpartum, and this was especially apparent in symptomatic cases such as those with dyspnea or worsening of edema and in those with worsened NYHA class. Attenhofer Jost et al¹⁶ also found that CTR greater than 0.65 was related to a poor prognosis in Ebstein anomaly, and women with increase in CTR had the worst outcomes of pregnancy and postpartum. Therefore, our findings and those of Attenhofer Jost et al indicate that worsening of CTR is useful for the prediction of maternal outcome.

However, it has been reported that Ebstein patients tolerate pregnancy well.^{5,7,8} In an investigation of 12 pregnancies complicated by Ebstein anomaly, Donnelly et al⁸ found that mild dyspnea was a common symptom in the third trimester but was no more troublesome


than that described in normal pregnancy, except for 1 case. However in our series, there were 2 early terminations of pregnancy because of heart failure and complications of a mechanical valve, 3 patients needed diuretics because of progression of edema, 1 dropped to NYHA class III in the postdelivery course, and 2 showed recurrent PSVT during pregnancy. In total, 7 patients showed some cardiac symptoms during pregnancy and 1 had deteriorated cardiac function after delivery in our series. Therefore, unique strategies for reducing the risk in pregnancy could include arrhythmia control by catheter ablation and bioprosthetic valve replacement before pregnancy in a case with symptoms because of these complications.

In our patients, even some in NYHA class I at conception, developed PSVT and NSVT, which indicates that arrhythmia during pregnancy is a concern in patients with Ebstein anomaly and that the outcome of pregnancy may not always be good in these patients.

In our study, the severity of TR did not progress during pregnancy and postpartum. In a normal pregnancy, systemic vascular resistance decreases to 70% of the level of the nonpregnant state until 16 weeks and then maintains this level until the end of the second trimester.¹⁷ This decreased afterload is beneficial for patients with Ebstein anomaly with mild cardiomegaly and mild TR, and such patients tolerated pregnancy well. Most cases with moderate to severe TR developed cardiomegaly with CTR of greater than 0.6 during pregnancy and postpartum in our series, and Celermajer et al¹⁸ found that late hemodynamic deterioration in Ebstein anomaly may be due to increased right or left heart failure or both.

Our findings and those of Celermajer et al¹⁸ indicate that NYHA functional class and prepregnancy severity of TR may be predictive of worsening of maternal and fetal outcome. And echocardiography is the most important diagnostic test in Ebstein's anomaly, permitting accurate assessment of the anatomy and distal attachments of the tricuspid valve, the size and contractility of the functional right ventricle, and the overall grade of disease

FIGURE 3
Changes of NYHA classification in the course of pregnancy



CTR, cardiothoracic ratio; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association.

Katsuragi. Ebstein anomaly in pregnancy. *Am J Obstet Gynecol* 2013.

severity. However, patients with Ebstein anomaly are also susceptible to supraventricular tachycardia, and WPW syndrome is present in 20-50% of these patients.¹⁹ However, arrhythmias in patients with Ebstein anomaly are not a contraindication to become pregnant. During pregnancy, supraventricular tachycardia can be treated with adenosine triphosphate or verapamil without adverse effects on the fetus, or direct current cardioversion can be used to safely terminate these arrhythmias. However, in such cases, we suggest that catheter ablation should be performed before conception for a subsequent pregnancy.²⁰

If the patients are symptomatic, including exercise intolerance and cyanotic or progressive cardioamegaly up to CTR of 65%, TVR should be considered.²¹ However, TVR with a mechanical valve is best avoided in patients who want to become pregnant, in case an anticoagulant is required during pregnancy. Both heparin and warfarin can be used during pregnancy, but use of warfarin may cause fetal brain hemorrhage and carries a risk of fetal bone anomaly, whereas heparin may cause maternal hemorrhage, as in one of our cases. A hypercoagulable state

may occur during pregnancy and a higher anticoagulant dose is needed as the glomerular filtration rate is increased.

Ebstein disease accounts for only 0.5% of congenital heart disease. Therefore, patients with Ebstein disease in pregnancy are relatively rare, and we were able to include only 13 such patients in our study. The small number of subjects prevented correction of the results for the effects of potential confounding factors such as hypertension and obstetric history through performance of multifactorial analysis. No newborn had congenital heart disease, but this needs to be reevaluated in a larger cohort. Also, few patients had undergone tricuspid valve repair, and this does not allow a discussion of this issue. In future work, we plan to investigate a larger cohort of patients to clarify the risk factors for cardiac dysfunction during pregnancy in patients with Ebstein anomaly.

In summary, pregnancy in Ebstein anomaly can be complicated with tachyarrhythmia or cardiac failure, and cardiac dysfunction and arrhythmias are a particular concern in post-TVR cases. However, maternal and fetal outcomes

are generally good without cardiac failure in patients with Ebstein anomaly with NYHA class I. Maternal outcome in these cases can be predicted by the preconceptional cardiac condition and NYHA functional class, which allows the evaluation of the risk for patients with Ebstein anomaly who want to become pregnant.

ACKNOWLEDGMENTS

We are indebted to the medical technologists at the National Cerebral and Cardiovascular Center for their important contributions to the study.

REFERENCES

- Perloff JK. The clinical recognition of congenital heart disease, 5th ed. Philadelphia: WB Saunders; 2003.
- Dearani JA, Danielson GK. Congenital heart surgery nomenclature and database project: Ebstein's anomaly and tricuspid valve disease. *Ann Thorac Surg* 2000;69:S106-17.
- Frescura C, Angelini A, Daliento L, Thiene G. Morphological aspects of Ebstein's anomaly in adults. *Thorac Cardiovasc Surg* 2000;48:203-8.
- Edwards WD. Embryology and pathologic features of Ebstein's anomaly. *Prog Pediatr Cardiol* 1993;2:5-15.
- Chopra S, Suri V, Aggarwal N, Rohilla M, Vijayvergiya R, Keepanasseril A. Ebstein's anomaly in pregnancy: maternal and neonatal outcomes. *J Obstet Gynaecol Res* 2010;36:278-83.
- Silversides CK, Kiess M, Beauchesne L, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan's syndrome. *Can J Cardiol* 2010;26:e80-97.
- Connolly HM, Warnes CA. Ebstein's anomaly: outcome of pregnancy. *J Am Coll Cardiol* 1994;23:1194-8.
- Donnelly JE, Brown JM, Radford DJ. Pregnancy outcome and Ebstein's anomaly. *Br Heart J* 1991;66:368-71.
- Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th ed revised. Boston: Little, Brown & Co; 1994.
- Moghbeli N, Pare E, Webb G. Practical assessment of maternal cardiovascular risk in pregnancy. *Congenit Heart Dis* 2008;3:308-16.
- Davies GA, Herbert WN. Congenital heart disease in pregnancy. *J Obstet Gynaecol Can* 2007;29:409-14.
- Gelson E, Curry R, Gatzoulis MA, et al. Effect of maternal heart disease on fetal growth. *Obstet Gynecol* 2011;117:886-91.
- Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. *BMJ* 1997;315:32-4.

14. Farquharson RG, Jauniaux E, Exalto N. ESHRE Special Interest Group for Early Pregnancy (SIGEP). Updated and revised nomenclature for description of early pregnancy events. *Hum Reprod* 2005;20:3008-11.
15. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). *N Engl J Med* 1988;319:1127-34.
16. Attenhofer Jost CH, Connolly HM, Dearani JA, Edwards WD, Danielson GK. Ebstein's anomaly. *Circulation* 2007;115:277-85.
17. Stevenson JC, Macdonald DW, Warren RC, Booker MW, Whitehead MI. Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy. *Br Med J* 1986;293:1329-30.
18. Celermajer DS, Bull C, Till JA, et al. Ebstein's anomaly: presentation and outcome from fetus to adult. *J Am Coll Cardiol* 1994;23:170-6.
19. Loomba RS, Chandrasekar S, Sanan P, Shah PH, Arora RR. Association of atrial tachyarrhythmias with atrial septal defect, Ebstein's anomaly and Fontan patients. *Expert Rev Cardiovasc Ther* 2011;9:887-93.
20. Miyazaki A, Sakaguchi H, Ohuchi H, et al. Efficacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot. *Circ J* 2012;76:2855-62.
21. Attenhofer Jost CH, Connolly HM, Edwards WD, Hayes D, Warnes CA, Danielson GK. Ebstein's anomaly—review of a multifaceted congenital cardiac condition. *Swiss Med Wkly* 2005;135:269-81.

PERINATAL/NEONATAL CASE PRESENTATION

Acute aortic dissection (Stanford type B) during pregnancy

S Katsuragi¹, R Neki¹, J Yoshimatsu¹, T Ikeda¹, H Morisaki² and T Morisaki²

We report a case of acute aortic dissection (Stanford type B) that occurred in pregnant woman at 34-week gestation. She had no systemic characteristics of Marfan syndrome, however she exhibited a mutation of *FBN1*, Arg 545 Cys, which has been found to correlate with ectopia lentis but not with aortic dissection.

Journal of Perinatology (2013) **33**, 484–485; doi:10.1038/jp.2012.123

Keywords: aortic dissection; gene analysis; pregnancy

INTRODUCTION

Pregnancy is strongly associated with life-threatening problems in Marfan patients. Herein, we report a case of aortic dissection during pregnancy with a rare combination of the clinical manifestation and *FBN1* mutation.

CASE

A 31-year-old woman, 2 gravida 1 para, was referred to our hospital at 34-week gestation because of acute aortic dissection type B. She had no family history of aortic dissection, or sudden death. She was 167 cm tall and weighed 80 kg before pregnancy. She had experienced sudden severe pain in her chest and was transferred to a tertiary care center. She was conscious and alert. She did not show either thumb sign, wrist sign or hind foot deformity in physical examination. Her arm span/height ratio was 1.02 (<1.05). Her blood pressure (BP) was 110~140 mmHg, heart rate 80 b.p.m., oxygen saturation SpO₂ 99~100%, cardiac ultrasonography revealed good left ventricular ejection fraction of 74%, left ventricle end-diastolic dimension/end-systolic dimension of 53/33 mm. She did not exhibit mitral valve prolapse or aortic valve regurgitation, or dilatation of ascending aorta. Tricuspid valve regurgitation was minimal, the diameter of the inferior vena cava was 16 mm, and there were no indications of pulmonary arterial hypertension. Electrocardiography showed no specific ST changes. Contrast computerized tomography showed aortic dissection from just after the branch of the left subclavian artery to the level of the atrium, but did not show dura ectasia. To control the BP, Nicardipine 3 ml per hour (0.5 γ) was started and the BP was maintained at around 110~120/mm Hg.

Fentanyl (0.5 mg per day) was administered as an analgesia. Three hours later, she felt another chest pain and the dissected area progressed to the level of the renal artery and she was transferred to our hospital. She was conscious and alert, with BP 124/60, heart rate 110 b.p.m. There was no sign of rales and the respiratory rate was 20 per minute. She had no clinical features suggestive of Marfan syndrome. The fetus was in position for cephalic presentation and the estimated fetal body weight was 2200 g. Cardiotocography reassured that the fetus was in no difficulty. As celiac, supra mesenteric and renal arterial blood flow

was adequate with no elevation of lactate level, there was no indication for the operation for the aortic dissection.

As the baby was mature enough for extra-uterine life and the mother required further intensive care, including BP control, pain control and follow-up CT scan examination, we decided to perform cesarean section. Cesarean section was performed under general anesthesia, and a 2350 g healthy baby was delivered. During the postpartum course, for BP control, Nicardipine was continued with 0.5 γ and dose was increased to 2.5 γ when she was extubated the next day and was maintained until 7 days postpartum. For the pain control Loxoprophen 120 mg per day was started on the day 1 postpartum, and maintained for 7 days.

The patient increased her activities incrementally each day after the surgery. Schellong test and 50-m walking test was performed on the day 3 and 7 postpartum, respectively, and there were no changes in her BP or heart rate. The patient was discharged from the hospital on the day 10 postpartum with no changes in the dissected areas. The genetic study was performed by direct sequencing of genomic DNA from peripheral blood leukocytes and complementary DNA from fibroblast RNA derived from intraoperative skin biopsy. Study results revealed a heterozygous missense mutation of c.1633C to T (p.Arg545Cys) in *FBN1* gene.

DISCUSSION

This patient had a missense mutation of *FBN1* (p.Arg545Cys), which has been specifically observed in six patients with lens subluxation in previous reports.^{1–4} The patient developed descending aortic dissection, but had no enlargement of the ascending aorta, which might not be typical of aortic lesions in Marfan syndrome, though Marfan patients with aortic dissection in the descending aorta were reported.^{5,6} Furthermore, no physical findings specific to Marfan syndrome were observed in this patient. Although aortic dissection is a rare complication that can develop during pregnancy,^{7,8,12} pregnancy is strongly associated with life-threatening problems particularly in Marfan patients.^{8,9} Aortic dissection events in pregnancy were reviewed in the aspect of its prevalence, etiology and subtypes of type A and type B, previously.^{10,11} The risk of aortic dilatation or dissection increases during and after pregnancy in patients with Marfan syndrome due to superimposition of the hyperdynamic and

¹Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Osaka, Japan and ²Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan. Correspondence: Dr S Katsuragi, Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.

E-mail: skatsura12@yahoo.co.jp

Received 13 April 2012; revised 30 August 2012; accepted 6 September 2012

hypervolemic circulatory state of pregnancy on the preexisting weakness of the aortic media.⁹ Marfan syndrome is an autosomal dominant connective tissue disorder, and is associated with a higher risk of aortic dissection.^{13–15} The above-mentioned results suggests that we should explain the genetics of the disease and provide genetic diagnosis, such as *FBN1*, for aortic dissection patients during pregnancy in order to identify the possible risk of aortic dissection, even if they are not considered as having Marfan syndrome.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- 1 Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene *FBN1* because of suspected Marfan syndrome. *Arch Intern Med* 2001; **161**: 2447–2454.
- 2 Hayward C, Porteous ME, Brock DJ. Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations. *Hum Mutat* 1997; **10**(4): 280–289.
- 3 Comeglio P, Evans AL, Brice G, Cooling RJ, Child AH. Identification of *FBN1* gene mutations in patients with ectopia lentis and marfanoid habitus. *Br J Ophthalmol* 2002; **86**(12): 1359–1362.
- 4 Lönnqvist L, Child A, Kainulainen K, Davidson R, Puhakka L, Peltonen L. A novel mutation of the fibrillin gene causing ectopia lentis. *Genomics* 1994; **19**(3): 573–576.
- 5 Brautbar A, LeMaire SA, Franco LM, Coselli JS, Milewicz DM, Belmont JW. *FBN1* mutations in patients with descending aortic dissections. *Am J Med Genet* 2010; **152A**: 413–416.
- 6 Adès LC, Holman KJ, Brett MS, Edwards MJ, Bennetts B. Ectopia lentis phenotype and *FBN1* gene. *Am J Med Genet* 2004; **126A**: 284–289.
- 7 Houston L, Tuuli M, Macones G. Marfan syndrome and aortic dissection in pregnancy. *Obstet Gynecol* 2010; **115**(2 Pt 2): 460–462.
- 8 Immer FF, Bansal AG, Immer-Bansal AS, McDougall J, Zehr KJ, Schaff HV et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. *Ann Thorac Surg* 2003; **76**: 309–314.
- 9 Lipscomb KJ, Smith JC, Bernard C, Donnai P, Harris R. Outcome of pregnancy in women with Marfan's syndrome. *Br J Obstet Gynaecol* 1997; **104**: 201–206.
- 10 Rosenberger LH, Adams JD, Kern JA, Tracci MC, Angle JF, Cherry KJ. Complicated postpartum type B aortic dissection and endovascular repair. *Obstet Gynecol* 2012; **119**: 480–483.
- 11 Braverman AC. Acute aortic dissection, clinical update. *Circulation* 2010; **122**: 184–188.
- 12 Pacini L, Digne F, Boumendil A, Muti C, Detaint D, Boileau C et al. Maternal complication of pregnancy in Marfan syndrome. *Int J Cardiol* 2009; **136**: 156–161.
- 13 Goland S, Elkayam Y. Cardiovascular problems in pregnant women with Marfan syndrome. *Circulation* 2009; **119**: 619–623.
- 14 Judge DP, Diez HC. Marfan's syndrome. *Lancet* 2005; **336**: 1965–1976.
- 15 Ammash NM, Sundt TM, Connolly HM. Marfan syndrome-diagnosis and management. *Curr Probl Cardiol* 2008; **31**: 7–39.



Safety and Efficacy of Implantable Cardioverter-Defibrillator During Pregnancy and After Delivery

Takekazu Miyoshi, MD; Chizuko A. Kamiya, MD; Shinji Katsuragi, MD;
Hiroto Ueda, MD; Yoshinari Kobayashi, MD; Chinami Horiuchi, MD; Kaoru Yamanaka, MD;
Reiko Neki, MD; Jun Yoshimatsu, MD; Tomoaki Ikeda, MD; Yuko Yamada, MD;
Hideo Okamura, MD; Takashi Noda, MD; Wataru Shimizu, MD

Background: There are few studies of pregnancy and delivery in patients with an implantable cardioverter-defibrillator (ICD). The purpose of this study was to investigate maternal and fetal outcome in these patients.

Methods and Results: Six pregnant women with an ICD were retrospectively reviewed. All women underwent implantation of an ICD before pregnancy and delivered at the National Cerebral and Cardiovascular Center. The mean age at pregnancy and the mean follow-up period after ICD implantation were 28 ± 3 years old and 5 ± 3 years, respectively. There was no device-related complication during pregnancy. In 4 women, the number of tachyarrhythmias such as non-sustained ventricular tachycardia increased after the end of the second trimester of pregnancy and anti-arrhythmic medications were gradually increased. No patient received discharges or shocks from the ICD during pregnancy, however, and only one required anti-tachycardia pacing at 27 weeks' gestation. Mean gestational age at delivery was 37 ± 2 weeks and all deliveries were by cesarean section, including 5 as emergency deliveries due to a fetal indication. After delivery, 2 mothers had reduced cardiac function and 1 received an ICD shock for the first time.

Conclusions: Pregnancy did not increase the risk of an ICD-related complication under appropriate management. Additional caution might be required in the postpartum period as well as during pregnancy and labor. (*Circ J* 2013; **77**: 1166–1170)

Key Words: Beta-blocker; Delivery; Implantable cardioverter-defibrillator; Pregnancy; Ventricular tachycardia

Cardiac disease complicates approximately 1% of all pregnancies, and women with arrhythmias comprise only a small number of these cases.¹ Although arrhythmias are uncommon during pregnancy, they may jeopardize the health of both mother and fetus. Ventricular tachyarrhythmia may be triggered during pregnancy as a result of hemodynamic changes and autonomic nervous system modification.^{2,3} Recurrence of malignant ventricular arrhythmias can be treated by defibrillation and anti-tachycardia pacing (ATP) to prevent sudden cardiac arrest.⁴ An implantable cardioverter-defibrillator (ICD) improves survival in patients with life-threatening arrhythmias.⁵ The number of women with congenital heart disease continues to increase and the use of an ICD has resulted in an increasing number of these women reaching a reproductive age.⁶ Natale et al performed a multicenter retrospective analysis of 44 pregnant women with ICDs and found that the majority completed and tolerated pregnancy without serious

complications.⁷ There are few studies, however, of pregnancy with an ICD managed at a single center and it remains unclear how to manage pregnant women with ICDs. The aim of this study was to investigate the maternal and fetal outcomes in these patients during pregnancy and after delivery.

Editorial p 1146

Methods

Study Design

The subjects were all pregnant women with an implanted ICD who delivered at the National Cerebral and Cardiovascular Center. Data were retrospectively collected for age at the time of initial ICD implantation and delivery; heart disease and arrhythmia; New York Heart Association class; anti-arrhythmic medications and other anti-arrhythmic treatment; indication

Received October 10, 2012; revised manuscript received October 26, 2012; accepted December 10, 2012; released online December 29, 2012 Time for primary review: 11 days

Department of Perinatology and Gynecology (T.M., C.A.K., S.K., H.U., Y.K., C.H., K.Y., R.N., J.Y., T.I.), Department of Cardiovascular Medicine (Y.Y., H.O., T.N., W.S.), National Cerebral and Cardiovascular Center, Suita, Japan

Mailing address: Takekazu Miyoshi, MD, Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan. E-mail: gomiyoshi0327@yahoo.co.jp

ISSN-1346-9843 doi:10.1253/circj.CJ-12-1275

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp

Table 1. Baseline Pre-Pregnancy Patient Characteristics

Patient	Heart disease	NYHA class	Age at ICD implantation (years)	LVEF at ICD implantation (%)	No. ICD shocks	Anti-arrhythmic medication	Other treatment
1	DCM, VT	2	25	37.5	0	Metoprolol	Catheter ablation
2	DCM, VF	2	23	21.3	2	Carvedilol, Mexiletine, Aprindine, Digoxin	
3	CHD†, VF	1	30	73.4	0	Mexiletine, Propranolol	
4	SSS, VT, PAF	1	26	62.7	16	Propranolol	PMI (DDD)
5	LQTS type 1	1	14	68.2	3	Atenolol	
6	LQTS type 2	1	26	56.5	0	Propranolol	
Mean±SD			25±6	53±20			

†Repair of coarctation of the aorta and patent ductus arteriosus, and aortic valve replacement for congenital bicuspid aortic valve.

CHD, congenital heart disease; DCM, dilated cardiomyopathy; DDD, dual-chamber inhibits and triggers; ICD, implantable cardioverter-efibrillator; LQTS, long QT syndrome; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAF, paroxysmal atrial fibrillation; PMI, pacemaker implantation; SSS, sick sinus syndrome; VF, ventricular fibrillation; VT, ventricular tachycardia.

for ICD implantation; device information; device-related complications; number of ICD discharges and shocks; gestational age at delivery; mode of delivery; total blood loss at delivery; device status at time of delivery; and fetal and neonatal complications.

Data for maternal age, gestational age, left ventricular ejection fraction (LVEF), total blood loss during cesarean section, birth weight, and follow-up period are given as mean ± SD.

Device Implantation

All ICDs were implanted via transvenous placement of a ventricular lead for defibrillation and pacing using standard techniques under fluoroscopic guidance. Pacing, sensing and defibrillation thresholds were tested during implantation. The devices used were manufactured by Medtronic (Minneapolis, MN, USA), Guidant (St Paul, MN, USA), and Boston Scientific (Natick, MA, USA).

Management of Pregnancy and Delivery

Fetal growth restriction was defined as an estimated fetal body weight <−1.5 SD of the Japanese standard value. Non-reassuring fetal status was diagnosed by cardiotocogram. Induction and augmentation of labor was performed according to obstetric or maternal indications using i.v. oxytocin following mechanical cervical dilation. Epidural anesthesia was electively used to minimize hemodynamic changes arising from pain or bearing down during labor and after cesarean section.

Results

Baseline Characteristics

Six Japanese women with an ICD who delivered between 2006 and 2012 were enrolled in the study. The mean follow-up after ICD implantation was 5±3 years (range, 2–9 years). The baseline pre-pregnancy characteristics of the 6 patients are given in Table 1. The indication for ICD implantation was secondary prevention in all women.

Patient 1 had dilated cardiomyopathy (DCM) with spontaneous ventricular tachycardia (VT) causing hemodynamic instability, for which catheter ablation was not effective. Patient 2 had DCM with chronic heart failure and repeated ventricular fibrillation (VF) that required cardioversion. Patient 3 had congenital heart disease, including coarctation of the aorta and patent ductus arteriosus that had been repaired at 2 years old. Aortic regurgitation progressed gradually because of a congenital bicuspid aortic valve and the patient had cardiopulmonary

arrest caused by VF at 30 years of age. ICD implantation was performed following aortic valve replacement with a Carpentier-Edwards perimount valve. Patient 4 had sick sinus syndrome with repeated syncope and underwent permanent pacemaker implantation (dual-chamber inhibits and triggers) at 23 years old. This patient had wide QRS tachycardia, and ICD implantation was performed for spontaneous VT causing hemodynamic instability. This patient had experienced 16 ICD shocks in response to VF following paroxysmal atrial fibrillation (PAF) caused by acute pharyngitis. Patient 5 had repeated syncope once a year since 3 years of age and had been diagnosed with long QT syndrome type 1 on genetic testing at 10 years old. After introduction of atenolol at 18 years old, syncope reduced to once every 3 years. The severe long QT syndrome was linked to a double-point mutation in the potassium voltage-gated channel KQT-like subfamily, member 1 in re-testing at 25 years old. Her corrected QT time was 470–500ms. Patient 6 had experienced repeated syncope since 25 years of age and had been diagnosed with long QT syndrome type 2 on genetic testing at 26 years old. Her corrected QT time was 430–470ms.

Patients 1 and 4 had implanted dual-chamber ICDs with DDI pacing. The other 4 patients had implanted single-chamber ICDs with VVI pacing. All devices were programmed for the VF zone and 4 (patients 1–4) were also programmed for the VT zone with ATP such as burst and ramp pacing and cardioversion. Patient 2 had inappropriate ICD shocks due to sinus tachycardia, and the VT zone was used only for sensing before pregnancy. Patient 3 had no inappropriate ICD shocks due to discrimination of supraventricular tachycardia. Patient 4 received propranolol before pregnancy to avoid a recurrence of PAF during pregnancy.

Pregnancy and Labor

Baseline pregnancy and labor patient characteristics are given in Tables 2,3. There were no device-related complications. In 4 women the number of arrhythmias (patients 1–3, non-sustained VT; patient 4, PAF) increased after the end of the second trimester and anti-arrhythmic medications were gradually increased. During pregnancy, no patient received discharges or shocks from the ICD, and only 1 (patient 1) received ATP at 27 weeks' gestation. After ATP in patient 1, the detection zone was changed from 2 zones (VT 180beats/min with 3 burst ATPs; VF 240beats/min) to 3 zones (VT-1 160beats/min with 3 burst and 3 ramp ATPs; VT-2 180beats/min with 3 burst ATPs; VF 220beats/min).

Labor was induced as planned in 3 cases: 2 (patients 1, 2)